Systematic analysis of the IgG antibody immune response against varicella zoster virus (VZV) using a self-assembled protein microarray

Alessandro Ceroni, Sahar Sibani, Armin Baiker, Venkata Raveendra Pothineni, Susanne M. Bailer, Joshua LaBaer, Jürgen Haas, Colin J. Campbell

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

Varicella zoster virus (VZV) is a human herpesvirus encoding at least 69 distinct viral proteins which causes chickenpox after primary infection and shingles during reactivation and which is particularly important in pregnancy and immunocompromised patients. Current serodiagnostic tests are either based on whole cell lysates or glycoprotein preparations. In order to investigate the humoral immune response to VZV infection or vaccination in more detail, and to improve the currently available diagnostic assays, we developed a nucleic acid programmable protein array (NAPPA) containing all 69 VZV proteins and performed a detailed analysis of 68 sera from individuals with either no, a previous or an acute VZV infection. In addition to the known reactive glycoprotein antigens (ORF 5, ORF 14, ORF 31, ORF 37, ORF 68), we discovered IgG antibodies against a variety of other membrane (ORF 2, ORF 24), capsid (ORF 20, ORF 23, ORF 43) and tegument (ORF 53, ORF 9, ORF 11) proteins, as well as other proteins involved in virus replication and assembly (ORF 25, ORF 26, ORF 28) and the transactivator proteins ORF 12, ORF 62 and ORF 63. All of these antigens were only reactive in a subset of VZV-positive individuals. A subset of the newly identified VZV antigens was validated by western blot analysis. Using these seroreactive new VZV antigens, more sensitive assays and tests distinguishing between different clinical entities may be developed.

Original languageEnglish (US)
Pages (from-to)1604-1610
Number of pages7
JournalMolecular BioSystems
Volume6
Issue number9
DOIs
StatePublished - Sep 2010

Fingerprint

Protein Array Analysis
Human Herpesvirus 3
Open Reading Frames
Antibody Formation
Immunoglobulin G
Antigens
Virus Diseases
Glycoproteins
Proteins
Virus Assembly
Trans-Activators

ASJC Scopus subject areas

  • Biotechnology
  • Molecular Biology

Cite this

Systematic analysis of the IgG antibody immune response against varicella zoster virus (VZV) using a self-assembled protein microarray. / Ceroni, Alessandro; Sibani, Sahar; Baiker, Armin; Pothineni, Venkata Raveendra; Bailer, Susanne M.; LaBaer, Joshua; Haas, Jürgen; Campbell, Colin J.

In: Molecular BioSystems, Vol. 6, No. 9, 09.2010, p. 1604-1610.

Research output: Contribution to journalArticle

Ceroni, Alessandro ; Sibani, Sahar ; Baiker, Armin ; Pothineni, Venkata Raveendra ; Bailer, Susanne M. ; LaBaer, Joshua ; Haas, Jürgen ; Campbell, Colin J. / Systematic analysis of the IgG antibody immune response against varicella zoster virus (VZV) using a self-assembled protein microarray. In: Molecular BioSystems. 2010 ; Vol. 6, No. 9. pp. 1604-1610.
@article{fb3902fcfb9e46dbb8cd9c775916898b,
title = "Systematic analysis of the IgG antibody immune response against varicella zoster virus (VZV) using a self-assembled protein microarray",
abstract = "Varicella zoster virus (VZV) is a human herpesvirus encoding at least 69 distinct viral proteins which causes chickenpox after primary infection and shingles during reactivation and which is particularly important in pregnancy and immunocompromised patients. Current serodiagnostic tests are either based on whole cell lysates or glycoprotein preparations. In order to investigate the humoral immune response to VZV infection or vaccination in more detail, and to improve the currently available diagnostic assays, we developed a nucleic acid programmable protein array (NAPPA) containing all 69 VZV proteins and performed a detailed analysis of 68 sera from individuals with either no, a previous or an acute VZV infection. In addition to the known reactive glycoprotein antigens (ORF 5, ORF 14, ORF 31, ORF 37, ORF 68), we discovered IgG antibodies against a variety of other membrane (ORF 2, ORF 24), capsid (ORF 20, ORF 23, ORF 43) and tegument (ORF 53, ORF 9, ORF 11) proteins, as well as other proteins involved in virus replication and assembly (ORF 25, ORF 26, ORF 28) and the transactivator proteins ORF 12, ORF 62 and ORF 63. All of these antigens were only reactive in a subset of VZV-positive individuals. A subset of the newly identified VZV antigens was validated by western blot analysis. Using these seroreactive new VZV antigens, more sensitive assays and tests distinguishing between different clinical entities may be developed.",
author = "Alessandro Ceroni and Sahar Sibani and Armin Baiker and Pothineni, {Venkata Raveendra} and Bailer, {Susanne M.} and Joshua LaBaer and J{\"u}rgen Haas and Campbell, {Colin J.}",
year = "2010",
month = "9",
doi = "10.1039/c003798b",
language = "English (US)",
volume = "6",
pages = "1604--1610",
journal = "Molecular BioSystems",
issn = "1742-206X",
publisher = "Royal Society of Chemistry",
number = "9",

}

TY - JOUR

T1 - Systematic analysis of the IgG antibody immune response against varicella zoster virus (VZV) using a self-assembled protein microarray

AU - Ceroni, Alessandro

AU - Sibani, Sahar

AU - Baiker, Armin

AU - Pothineni, Venkata Raveendra

AU - Bailer, Susanne M.

AU - LaBaer, Joshua

AU - Haas, Jürgen

AU - Campbell, Colin J.

PY - 2010/9

Y1 - 2010/9

N2 - Varicella zoster virus (VZV) is a human herpesvirus encoding at least 69 distinct viral proteins which causes chickenpox after primary infection and shingles during reactivation and which is particularly important in pregnancy and immunocompromised patients. Current serodiagnostic tests are either based on whole cell lysates or glycoprotein preparations. In order to investigate the humoral immune response to VZV infection or vaccination in more detail, and to improve the currently available diagnostic assays, we developed a nucleic acid programmable protein array (NAPPA) containing all 69 VZV proteins and performed a detailed analysis of 68 sera from individuals with either no, a previous or an acute VZV infection. In addition to the known reactive glycoprotein antigens (ORF 5, ORF 14, ORF 31, ORF 37, ORF 68), we discovered IgG antibodies against a variety of other membrane (ORF 2, ORF 24), capsid (ORF 20, ORF 23, ORF 43) and tegument (ORF 53, ORF 9, ORF 11) proteins, as well as other proteins involved in virus replication and assembly (ORF 25, ORF 26, ORF 28) and the transactivator proteins ORF 12, ORF 62 and ORF 63. All of these antigens were only reactive in a subset of VZV-positive individuals. A subset of the newly identified VZV antigens was validated by western blot analysis. Using these seroreactive new VZV antigens, more sensitive assays and tests distinguishing between different clinical entities may be developed.

AB - Varicella zoster virus (VZV) is a human herpesvirus encoding at least 69 distinct viral proteins which causes chickenpox after primary infection and shingles during reactivation and which is particularly important in pregnancy and immunocompromised patients. Current serodiagnostic tests are either based on whole cell lysates or glycoprotein preparations. In order to investigate the humoral immune response to VZV infection or vaccination in more detail, and to improve the currently available diagnostic assays, we developed a nucleic acid programmable protein array (NAPPA) containing all 69 VZV proteins and performed a detailed analysis of 68 sera from individuals with either no, a previous or an acute VZV infection. In addition to the known reactive glycoprotein antigens (ORF 5, ORF 14, ORF 31, ORF 37, ORF 68), we discovered IgG antibodies against a variety of other membrane (ORF 2, ORF 24), capsid (ORF 20, ORF 23, ORF 43) and tegument (ORF 53, ORF 9, ORF 11) proteins, as well as other proteins involved in virus replication and assembly (ORF 25, ORF 26, ORF 28) and the transactivator proteins ORF 12, ORF 62 and ORF 63. All of these antigens were only reactive in a subset of VZV-positive individuals. A subset of the newly identified VZV antigens was validated by western blot analysis. Using these seroreactive new VZV antigens, more sensitive assays and tests distinguishing between different clinical entities may be developed.

UR - http://www.scopus.com/inward/record.url?scp=77957561151&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77957561151&partnerID=8YFLogxK

U2 - 10.1039/c003798b

DO - 10.1039/c003798b

M3 - Article

VL - 6

SP - 1604

EP - 1610

JO - Molecular BioSystems

JF - Molecular BioSystems

SN - 1742-206X

IS - 9

ER -